Keywords: Roche, Zelboraf, Metastatic melanoma, Vanderbilt-Ingram Cancer Center, Overall survival

Roche’s Zelboraf nearly doubles survival in majority of MM patients

Article | 23 February 2012

Print This

Investigators from Vanderbilt-Ingram Cancer Center (VICC) and 12 other centers in the USA and Australia have found that a new drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in